RCAP
UTHR icon

Resolute Capital Asset Partners’s United Therapeutics UTHR Stock Holding History

Resolute Capital Asset Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$5.93M – 62
2026
Q1 		$5.93M Buy
+10,000
New +$4.98M 3.12% 8

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Resolute Capital Asset Partners's UTHR Position: Q2 2026 in Review

Resolute Capital Asset Partners sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 10,000 shares — an estimated $5.93M sold.

Resolute Capital Asset Partners first reported a position in UTHR in Q1 2026 and held it in 1 quarter. The position peaked at $5.93M in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Resolute Capital Asset Partners reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 10,000 United Therapeutics shares in Q2 2026, an estimated $5.93M.
  • Resolute Capital Asset Partners first reported a position in United Therapeutics in Q1 2026 and held it in 1 quarter.
  • Resolute Capital Asset Partners's United Therapeutics position peaked at $5.93M in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q2 2026, filed 14 Aug 2026.